Why the study?
The comparative efficacy and safety of direct oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation and reduced creatinine clearance was unclear.
Do different DOACs have comparable efficacy and safety in patients with nonvalvular atrial fibrillation and reduced creatinine clearance?
Systematic Review
Do different DOACs have comparable efficacy and safety in patients with nonvalvular atrial fibrillation and reduced creatinine clearance?
In patients with atrial fibrillation and creatinine clearance <50 ml/min, apixaban appears to have a more favorable safety profile regarding major bleeding compared to rivaroxaban and dabigatran, with comparable efficacy.
Answers are grounded in this paper and cite their sources.
Favors apixaban over rivaroxaban in AF with CrCl <50 ml/min to reduce major bleeding; extends DOAC safety comparisons to renal impairment.
Aim To compare efficacy and safety of direct oral anticoagulants (DOACs) for prevention of stroke in patients with nonvalvular atrial fibrillation and reduced creatinine clearance.Material and methods Systematic search for literature and indirect comparison of DOACs were performed.Results The indirect comparison included five randomized clinical trials. The DOACs were comparable by the efficacy of preventing stroke and systemic embolism. The safety profiles had differences. Apixaban significantly decreased the relative risk of major bleeding compared to rivaroxaban by 27 % (relative risk (RR) 0.73; 95 % confidence interval (CI): 0.55-0.98). The apixaban advantage was even greater in the group of patients with a creatinine clearance <50 ml/min: RR was reduced by 48 % compared to rivaroxaban (RR=0.52; 95 % CI: 0.32-0.84), by 50 % compared to dabigatran 300 mg/day (RR=0.50; 95 % CI: 0.31-0.81), and by 48 % compared to dabigatran 220 mg/day (RR=0.52; 95 % CI: 0.32-0.85)Conclusion The indirect comparison of DOACs showed that their efficacy was comparable. With respect of safety, apixaban is the preferrable DOAC for patients with atrial fibrillation and creatinine clearance below 50 ml/min.
No takes yet. Share an insight, caveat, or question.
Gorbatenko et al. (2020) conducted a systematic review in nonvalvular atrial fibrillation and reduced creatinine clearance. Apixaban vs. Rivaroxaban was evaluated on major bleeding (RR 0.73, 95% CI 0.55-0.98).
Synapse has enriched 10 related papers. Consider them for comparative context: